PMID- 17169781
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20201215
IS  - 0883-0185 (Print)
IS  - 0883-0185 (Linking)
VI  - 25
IP  - 5-6
DP  - 2006 Sep-Dec
TI  - Dendritic cell-based immunotherapy.
PG  - 377-413
AB  - Dendritic cells (DCs) play a crucial role in the induction of antigen-specific 
      T-cell responses, and therefore their use for the active immunotherapy of 
      malignancies has been studied with considerable interest. More than a decade has 
      passed since the publication of the first clinical data of DC-based vaccines, and 
      through this and subsequent studies, a number of important developmental insights 
      have been gleaned. These include the ideal source and type of DCs, the discovery 
      of novel antigens and methods of loading DCs, the role of DC maturation, and the 
      most efficient route of immunization. The generation of immune responses against 
      tumor antigens after DC immunization has been demonstrated, and favorable 
      clinical responses have been reported in some patients; however, it is difficult 
      to pool the results as a whole, and thus the body of data remains inconclusive, 
      in part because of varying DC preparation and vaccination protocols, the use of 
      different forms of antigens, and, most importantly, a lack of rigorous criteria 
      for defining clinical responses. As such, the standardization of clinical and 
      immunologic criteria utilized, as well as DC preparations employed, will allow 
      for the comparison of results across multiple clinical studies and is required in 
      order for future trials to measure the true value and role of this treatment 
      modality. In addition, issues regarding the optimal dose and clinical setting for 
      the application of DC vaccines remain to be resolved, and recent clinical studies 
      have been designed to begin to address these questions.
FAU - Osada, Takuya
AU  - Osada T
AD  - Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer 
      Center, Duke University Medical Center, Durham, North Carolina 27710, USA.
FAU - Clay, Timothy M
AU  - Clay TM
FAU - Woo, Christopher Y
AU  - Woo CY
FAU - Morse, Michael A
AU  - Morse MA
FAU - Lyerly, H Kim
AU  - Lyerly HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Int Rev Immunol
JT  - International reviews of immunology
JID - 8712260
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/*immunology
MH  - Cancer Vaccines/*immunology
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Neoplasms/*immunology/therapy
RF  - 179
EDAT- 2006/12/16 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/12/16 09:00
PHST- 2006/12/16 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/12/16 09:00 [entrez]
AID - H2X6WQ4286071X73 [pii]
AID - 10.1080/08830180600992456 [doi]
PST - ppublish
SO  - Int Rev Immunol. 2006 Sep-Dec;25(5-6):377-413. doi: 10.1080/08830180600992456.